FR09C0004I2 - Pyrimidines comme inhibiteurs de reproduction du VIH - Google Patents

Pyrimidines comme inhibiteurs de reproduction du VIH

Info

Publication number
FR09C0004I2
FR09C0004I2 FR09C0004C FR09C0004C FR09C0004I2 FR 09C0004 I2 FR09C0004 I2 FR 09C0004I2 FR 09C0004 C FR09C0004 C FR 09C0004C FR 09C0004 C FR09C0004 C FR 09C0004C FR 09C0004 I2 FR09C0004 I2 FR 09C0004I2
Authority
FR
France
Prior art keywords
pyrimidines
inhibitors
hiv reproduction
hiv
reproduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0004C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of FR09C0004I1 publication Critical patent/FR09C0004I1/fr
Application granted granted Critical
Publication of FR09C0004I2 publication Critical patent/FR09C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR09C0004C 1998-11-10 2009-01-22 Pyrimidines comme inhibiteurs de reproduction du VIH Active FR09C0004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
FR09C0004I1 FR09C0004I1 (cg-RX-API-DMAC7.html) 2009-02-27
FR09C0004I2 true FR09C0004I2 (fr) 2010-06-11

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0004C Active FR09C0004I2 (fr) 1998-11-10 2009-01-22 Pyrimidines comme inhibiteurs de reproduction du VIH

Country Status (41)

Country Link
US (5) US6878717B2 (cg-RX-API-DMAC7.html)
EP (2) EP1270560B1 (cg-RX-API-DMAC7.html)
JP (1) JP3635238B2 (cg-RX-API-DMAC7.html)
KR (1) KR100658489B1 (cg-RX-API-DMAC7.html)
CN (1) CN1214013C (cg-RX-API-DMAC7.html)
AP (1) AP1683A (cg-RX-API-DMAC7.html)
AR (1) AR024227A1 (cg-RX-API-DMAC7.html)
AT (2) ATE233740T1 (cg-RX-API-DMAC7.html)
AU (2) AU762523C (cg-RX-API-DMAC7.html)
BG (1) BG65103B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI9915552B8 (cg-RX-API-DMAC7.html)
CA (1) CA2350801C (cg-RX-API-DMAC7.html)
CY (1) CY2008021I1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301367B6 (cg-RX-API-DMAC7.html)
DE (3) DE69941934D1 (cg-RX-API-DMAC7.html)
DK (1) DK1002795T3 (cg-RX-API-DMAC7.html)
EA (1) EA004049B1 (cg-RX-API-DMAC7.html)
EE (1) EE05086B1 (cg-RX-API-DMAC7.html)
ES (2) ES2193664T3 (cg-RX-API-DMAC7.html)
FR (1) FR09C0004I2 (cg-RX-API-DMAC7.html)
HK (1) HK1048817B (cg-RX-API-DMAC7.html)
HR (2) HRP20080359B1 (cg-RX-API-DMAC7.html)
HU (2) HU230394B1 (cg-RX-API-DMAC7.html)
ID (1) ID28376A (cg-RX-API-DMAC7.html)
IL (2) IL143023A0 (cg-RX-API-DMAC7.html)
LT (1) LTC1002795I2 (cg-RX-API-DMAC7.html)
LU (1) LU91528I2 (cg-RX-API-DMAC7.html)
MY (1) MY121108A (cg-RX-API-DMAC7.html)
NL (1) NL300373I2 (cg-RX-API-DMAC7.html)
NO (3) NO318801B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ511116A (cg-RX-API-DMAC7.html)
OA (1) OA11674A (cg-RX-API-DMAC7.html)
PL (1) PL204427B1 (cg-RX-API-DMAC7.html)
PT (1) PT1002795E (cg-RX-API-DMAC7.html)
SI (1) SI1002795T1 (cg-RX-API-DMAC7.html)
SK (2) SK287269B6 (cg-RX-API-DMAC7.html)
TR (1) TR200101306T2 (cg-RX-API-DMAC7.html)
TW (1) TWI238161B (cg-RX-API-DMAC7.html)
UA (1) UA70966C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000027825A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200103769B (cg-RX-API-DMAC7.html)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
HRP20020247B1 (hr) * 1999-09-24 2011-02-28 Janssen Pharmaceutica N.V. Antivirusni pripravci
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
DE60039059D1 (de) 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US7418471B2 (en) * 2000-11-01 2008-08-26 Snapnames.Com, Inc. Domain name acquisition and management system and method
WO2002096888A1 (de) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
DK1442019T3 (da) 2001-11-01 2008-01-14 Janssen Pharmaceutica Nv Amidderivater som glycogensynthasekinase 3- beta-inhibitorer
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20040801A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Sulfonylamino derivatives as novel inhibitors of histone deacetylase
ATE425152T1 (de) 2002-03-13 2009-03-15 Janssen Pharmaceutica Nv Aminocarbonylderivate als histone-deacetylase- inhibitoren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
NZ536294A (en) * 2002-05-03 2005-05-27 Janssen Pharmaceutica Nv Polymeric microemulsions of amphiphilic diblock copolymers
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
JP4822707B2 (ja) * 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US7585861B2 (en) * 2003-02-07 2009-09-08 Janssen Pharmaceutica, N.V. HIV inhibiting 1,2,4-triazines
AP2065A (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
EP1597251B1 (en) * 2003-02-20 2009-06-10 SmithKline Beecham Corporation Pyrimidine compounds
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US20060172010A1 (en) 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
MXPA06002069A (es) 2003-09-25 2006-05-19 Janssen Pharmaceutica Nv Derivados de purina que inhiben la replicacion del vih.
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
ES2442857T3 (es) 2004-08-10 2014-02-13 Janssen Pharmaceutica Nv Derivados de 1,2,4-triazin-6-ona inhibidores de VIH
CA2577467C (en) 2004-09-30 2013-05-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
RU2410379C2 (ru) 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
TW200626560A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
EP1807430B1 (en) 2004-10-29 2014-07-23 Janssen R&D Ireland Hiv inhibiting bicyclic pyrimidine derivatives
US20060106043A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and etravirine
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CN101107234B (zh) * 2005-01-27 2013-06-19 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
JP5247154B2 (ja) * 2005-02-18 2013-07-24 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性２−（４−シアノフェニルアミノ）ピリミジンオキシド誘導体
RS51435B (sr) * 2005-03-04 2011-04-30 Tibotec Pharmaceuticals 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
RU2458056C2 (ru) * 2005-05-26 2012-08-10 Тиботек Фармасьютикалз Лтд Способ получения 4-(1,6-дигидро-6-оксо-2-пиримидинил)амино-бензонитрила
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7754773B2 (en) * 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
CA2626375A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981875T3 (da) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
CN101370804B (zh) 2006-01-19 2013-05-29 詹森药业有限公司 作为组蛋白脱乙酰基酶抑制剂的新的氨基苯基衍生物
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2004632B1 (en) * 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
ES2353725T3 (es) 2006-03-30 2011-03-04 Tibotec Pharmaceuticals Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el vih.
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
NZ572702A (en) * 2006-06-06 2011-09-30 Tibotec Pharm Ltd Process for preparing spray dried formulations of etravirine in microcrystalline cellulose
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
JP5464584B2 (ja) * 2006-12-06 2014-04-09 ヤンセン・アールアンドデイ・アイルランド 抗ｈｉｖ化合物の臭化水素酸塩
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
MX2009007006A (es) 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8754093B2 (en) 2009-03-30 2014-06-17 Janssen R&D Ireland Co-crystal of etravirine and nicotinamide
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
WO2010150279A2 (en) 2009-06-22 2010-12-29 Emcure Pharmaceuticals Limited Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
EP2584901A4 (en) 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
TWI545115B (zh) 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
AU2011328139A1 (en) 2010-11-10 2013-04-04 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as LRRK2 modulators
PT2702045T (pt) 2011-04-26 2018-01-11 Mylan Laboratories Ltd Método inovador para a preparação de etravirina
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
EP4327886A3 (en) 2011-08-23 2024-05-22 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014068588A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of etravirine and its intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
RU2015126505A (ru) 2012-12-21 2017-01-27 Верликс Фарма Инк. Применение и способы лечения заболеваний и патологических состояний печени
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
JP7525264B2 (ja) 2017-04-28 2024-07-30 リベルタス バイオ，インコーポレイティド アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
DE3581570D1 (de) * 1984-06-25 1991-03-07 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
DD283613A5 (de) 1988-03-31 1990-10-17 ��@���������@�������k�� Verfahren zur herstellung von in 6-stellung substituierte acyclopyrimidin-nucleosid-derivaten
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
RU2153494C2 (ru) 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
SK67298A3 (en) 1995-11-23 1998-11-04 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
EP1282607B1 (en) * 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
US8003789B2 (en) 2011-08-23
WO2000027825A1 (en) 2000-05-18
PT1002795E (pt) 2003-07-31
SK6032001A3 (en) 2002-01-07
EE05086B1 (et) 2008-10-15
HRP20010161A2 (en) 2002-02-28
SK287269B6 (sk) 2010-05-07
EP1270560B1 (en) 2010-01-13
NO2009003I2 (no) 2010-06-07
BR9915552A (pt) 2001-08-14
KR100658489B1 (ko) 2006-12-18
HRP20080359A2 (en) 2008-12-31
TWI238161B (en) 2005-08-21
CY2008021I2 (el) 2010-07-28
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
NZ511116A (en) 2003-08-29
ATE233740T1 (de) 2003-03-15
ES2193664T3 (es) 2003-11-01
LU91528I9 (cg-RX-API-DMAC7.html) 2019-01-02
HRP20010161B9 (hr) 2014-10-24
LTC1002795I2 (lt) 2021-06-10
JP3635238B2 (ja) 2005-04-06
ZA200103769B (en) 2002-08-12
BR9915552B1 (pt) 2013-11-19
US20110263625A1 (en) 2011-10-27
PL347586A1 (en) 2002-04-08
US20040039005A1 (en) 2004-02-26
FR09C0004I1 (cg-RX-API-DMAC7.html) 2009-02-27
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
US7037917B2 (en) 2006-05-02
UA70966C2 (uk) 2004-11-15
HUP0104177A3 (en) 2003-01-28
US20050288278A1 (en) 2005-12-29
IL169949A (en) 2011-02-28
OA11674A (en) 2005-01-12
US8530655B2 (en) 2013-09-10
NL300373I1 (nl) 2009-03-02
CA2350801C (en) 2008-05-20
HK1025330A1 (en) 2000-11-10
NO2021015I1 (no) 2021-03-29
BRPI9915552B8 (pt) 2021-05-25
BG65103B1 (bg) 2007-02-28
HU230394B1 (hu) 2016-04-28
EP1002795A1 (en) 2000-05-24
CZ20011533A3 (cs) 2001-10-17
HK1048817B (en) 2010-04-09
ES2338760T3 (es) 2010-05-12
EA200100536A1 (ru) 2002-02-28
PL204427B1 (pl) 2010-01-29
DE122009000003I1 (de) 2009-05-20
CY2008021I1 (el) 2010-07-28
HRP20080359B1 (hr) 2016-01-01
EP1002795B1 (en) 2003-03-05
HRP20010161B1 (en) 2009-03-31
DE69941934D1 (de) 2010-03-04
CA2350801A1 (en) 2000-05-18
EA004049B1 (ru) 2003-12-25
AU762523B2 (en) 2003-06-26
HK1048817A1 (en) 2003-04-17
TR200101306T2 (tr) 2001-10-22
NO20011696L (no) 2001-04-04
NL300373I2 (nl) 2009-04-01
ATE455107T1 (de) 2010-01-15
AU6200899A (en) 2000-05-29
LU91528I2 (fr) 2009-04-20
JP2002529456A (ja) 2002-09-10
KR20010075235A (ko) 2001-08-09
AP1683A (en) 2006-11-29
BG105418A (en) 2001-11-30
IL143023A0 (en) 2002-04-21
LTPA2008016I1 (lt) 2021-04-26
MY121108A (en) 2005-12-30
EP1270560A1 (en) 2003-01-02
US20080176880A1 (en) 2008-07-24
AU762523C (en) 2004-02-12
US6878717B2 (en) 2005-04-12
HUP0104177A2 (hu) 2002-03-28
NO318801B1 (no) 2005-05-09
AU2011200708A1 (en) 2011-03-10
CZ301367B6 (cs) 2010-02-03
AR024227A1 (es) 2002-09-25
NO20011696D0 (no) 2001-04-04
HU227453B1 (en) 2011-06-28
NO2009003I1 (no) 2009-03-09
CN1322198A (zh) 2001-11-14
EE200100252A (et) 2002-10-15
CN1214013C (zh) 2005-08-10
SI1002795T1 (en) 2003-10-31
DE69905683T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
FR09C0004I2 (fr) Pyrimidines comme inhibiteurs de reproduction du VIH
PT945132E (pt) Composicao de ibuprofeno
NO20004219D0 (no) Inhibitorer av fosfolipaseenzymer
NO20004220L (no) Inhibitorer av fosfolipaseenzymer
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DE69941116D1 (de) G von gdf-8
DE60028307D1 (de) Eliminierung von interferenzsignalen
PT817613E (pt) Utilizacao de composicoes compreendendo enzimas estabilizadas
PT1200065E (pt) Composicao de ovulos intravaginais de clindamicina
CY2006003I2 (el) Χρηση δαπτομυκινης
ID29021A (id) Komposisi galantamina pelepasan terkontrol
ID27092A (id) Pembuatan ftalat anhidrida
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
PT945443E (pt) Derivados de pirimidina inibidores de hiv
DK1064298T3 (da) Inhibitorer af caspaser
DZ3347A1 (fr) Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
FR08C0007I2 (fr) Derives du triazolyltropane utilises comme modulateurs de ccr5
NO20004550D0 (no) Enzyminhibitorer
EP1082121A4 (en) HIV integrase
PT927183E (pt) Inibidores espirociclicos de metaloproteases
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
EP1083897A4 (en) HIV INTEGRASE INHIBITORS
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
FR2767689B1 (fr) Utilisation de derives oxamates comme agents depigmentants
FR2816843B1 (fr) Inhibiteurs de l'enzyme 5 alpha-reductase